These results interrogate our in vitro and ex vivo results and the clinical data of patients, emphasizing the importance to investigate and harness acquired dependency (collateral sensitivity) resulting from tumor evolution and heterogeneity to treat KRAS-mutant lung cancer and perhaps other malignancies as well. Here, KRAS is linked to lung carcinoma.